ONC · XBRL financial data

BeOne Medicines financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (ONC's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Revenue from contracts with customers	781	634*	752	929	1,002	1,128*	1,117	1,315	1,412	1,498*	1,513	1,705
Cost of goods and services sold	96	—	—	—	—	—	—	—	—	—	—	—
Gross profit	685	—	627	791	831	—	952	1,151	1,216	—	1,346	1,531
Research and development	453	494*	461	454	496	542*	482	525	524	615*	541	612
Selling, general and administrative	364	417*	427	444	455	505*	459	538	529	555*	555	593
Operating income (loss)	(134)	(384)*	(261)	(107)	(120)	(79)*	11	88	163	185*	250	325
Interest income	—	year only	—	—	—	year only	13	11	—	year only	28	28
Interest expense	7	5*	12	13	14	7*	7	8	13	12*	33	40
Other income (expense)	337	17*	2	(12)	11	(14)*	4	8	(19)	(36)*	15	(1)
Income tax expense (benefit)	14	17*	8	14	23	67*	20	5	22	83*	32	75
Net income (loss)	215	(368)*	(251)	(120)	(121)	(152)*	1	94	125	67*	227	237
Earnings per share, basic USD per share	0.16	(0.27)*	(0.19)	(0.09)	(0.09)	(0.11)*	0.00	0.07	0.09	0.05*	0.16	0.16
Earnings per share, diluted USD per share	0.15	(0.28)*	(0.19)	(0.09)	(0.09)	(0.11)*	0.00	0.06	0.08	0.04*	0.15	0.16
Weighted average shares, basic millions of shares	1,361	1,353*	1,356	1,361	1,377	1,381*	1,390	1,408	1,433	1,439*	1,442	1,450
Weighted average shares, diluted millions of shares	1,390	1,323*	1,356	1,361	1,377	1,381*	1,445	1,463	1,489	1,501*	1,505	1,505

Balance sheet

CSV

Fiscal quarters (ONC's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	3,067	3,172	2,793	2,593	2,702	2,627	2,516	2,756	4,037	4,548	4,792	5,098
Short-term investments	—	3	—	—	—	—	—	—	—	—	—	—
Accounts receivable	309	358	435	529	569	676	717	771	863	865	938	1,056
Inventory	317	416	447	443	432	495	495	503	532	608	682	733
Prepaid and other current assets	242	243	232	274	209	193	168	281	233	213	190	329
Total current assets	4,054	4,203	3,908	3,839	3,912	3,992	3,896	4,310	5,664	6,234	6,601	7,216
Property and equipment, net	1,178	1,324	1,418	1,516	1,563	1,578	1,599	1,616	1,628	1,642	1,641	1,643
Right-of-use asset	99	95	88	104	101	139	146	146	140	148	145	146
Total assets	5,525	5,805	5,668	5,712	5,831	5,921	5,842	6,298	7,633	8,189	8,554	9,176
Accounts payable	342	315	357	333	308	405	364	361	384	479	424	470
Accrued liabilities	506	694	569	647	717	804	692	909	1,002	1,109	1,079	1,264
Current portion of long-term debt	329	688	827	852	864	852	763	808	—	57	116	191
Total current liabilities	1,283	1,810	1,882	1,939	2,025	2,215	1,984	2,210	2,368	1,829	1,812	2,119
Long-term debt	202	198	199	185	188	166	160	146	—	962	963	882
Lease liability, non-current	25	22	18	35	32	44	55	54	51	53	50	48
Total liabilities	1,762	2,268	2,307	2,346	2,395	2,589	2,342	2,528	3,503	3,827	3,793	4,002
Accumulated deficit	(7,594)	(7,962)	(8,213)	(8,334)	(8,455)	(8,607)	(8,606)	(8,511)	(8,386)	(8,320)	(8,093)	(7,856)
Total stockholders' equity	3,763	3,537	3,360	3,366	3,436	3,332	3,500	3,770	4,129	4,361	4,760	5,174
Total liabilities and equity	5,525	5,805	5,668	5,712	5,831	5,921	5,842	6,298	7,633	8,189	8,554	9,176
Common shares outstanding (cover page) millions of shares	1,359	1,360	1,360	1,380	1,386	1,387	1,403	1,430	1,439	1,442	1,445	1,478

Cash flows

CSV

Fiscal quarters (ONC's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	215	(368)*	(251)	(120)	(121)	(152)*	1	94	125	67*	227	237
Stock-based compensation	96*	93*	89	131*	115*	108*	95	151*	141*	124*	123	137*
Depreciation and amortization	22*	24*	25	25*	71*	50*	33	36*	37*	36*	41	41*
Net cash from operating activities	(78)*	(222)*	(309)	(96)*	188*	75*	44	264*	403*	417*	201	463*
Purchases of property and equipment	158*	157*	157	110*	134*	92*	56	44*	48*	38*	41	27*
Net cash from investing activities	(186)*	(63)*	(210)	(111)*	(134)*	(94)*	(122)	(67)*	(49)*	(38)*	(46)	(49)*
Proceeds from issuing common stock	—	year only	—	—	—	—	—	—	—	—	—	—
Repayments of long-term debt	8*	5*	4	10*	4*	10*	4	13*	4*	15*	8	17*
Net cash from financing activities	(77)*	347*	162	23*	13*	(5)*	(34)	35*	961*	97*	69	(6)*
Net change in cash	(341)*	105*	(379)	(190)*	95*	(75)*	(108)	255*	1,324*	499*	244	427*

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
BeOne Medicines	5,098	1,705	463*	1.5B	—	Q2 FY26 10-QJun 30, 2026
Teva Pharmaceutical Industries	4,085	4,395	241	1.2B	—	Q3 FY26 10-QSep 30, 2026
Biogen	1,304	2,804	641*	147.8M	—	Q3 FY26 10-QSep 30, 2026
United Therapeutics	1,189	833	not reported	42.6M	—	Q3 FY26 10-QSep 30, 2026
INSMED	397	524	(36)*	219.4M	—	Q3 FY26 10-QSep 30, 2026
Roivant Sciences	1,248	1.4	(271)	722.3M	14.2 quarters	Q1 FY26 10-QJun 30, 2026
Neurocrine Biosciences	642	1,123	395*	101.2M	—	Q3 FY26 10-QSep 30, 2026
Exelixis	305	659	280*	244.0M	—	Q3 FY26 10-QOct 2, 2026
BIO-TECHNE	265	321*	95*	156.8M	—	Q4 FY26 10-KJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.